Saturday, September 19, 2009
Antigenics (AGEN)
When I see this kind of chart for a stock (weekly as well as daily charts), my attention is automatically triggered.
In the past, each time the price came back to touch the 50 day moving average, it thereafter rebounded. Will it happen this time?
A few words about Antigenics (ticker: AGEN, listed on the Nasdaq):
Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment